The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
116277856 11627785 6 F 20130223 20160826 20151014 20160901 EXP CA-ROCHE-1645417 ROCHE 65.19 YR F Y 0.00000 20160901 MD CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
116277856 11627785 1 PS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 150 MG SOLUTION FOR INJECTION
116277856 11627785 2 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 3 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 4 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 5 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 6 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 7 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 8 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 9 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 10 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 11 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0001E 103976 SOLUTION FOR INJECTION
116277856 11627785 12 C ZENHALE FORMOTEROL FUMARATEMOMETASONE FUROATE 1 Unknown U 0
116277856 11627785 13 C SPIRIVA TIOTROPIUM BROMIDE MONOHYDRATE 1 Unknown U 0
116277856 11627785 14 C SINGULAIR MONTELUKAST SODIUM 1 Unknown U 0
116277856 11627785 15 C ALVESCO CICLESONIDE 1 Unknown U 0
116277856 11627785 16 C VENTOLIN ALBUTEROL SULFATE 1 Unknown U 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
116277856 11627785 1 Asthma
116277856 11627785 12 Product used for unknown indication
116277856 11627785 13 Product used for unknown indication
116277856 11627785 14 Product used for unknown indication
116277856 11627785 15 Product used for unknown indication
116277856 11627785 16 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
116277856 11627785 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
116277856 11627785 Anaphylactoid reaction
116277856 11627785 Back pain
116277856 11627785 Body temperature decreased
116277856 11627785 Cough
116277856 11627785 Diarrhoea
116277856 11627785 Dizziness
116277856 11627785 Dry throat
116277856 11627785 Epistaxis
116277856 11627785 Facial bones fracture
116277856 11627785 Faeces discoloured
116277856 11627785 Fall
116277856 11627785 Fatigue
116277856 11627785 Formication
116277856 11627785 Gingival disorder
116277856 11627785 Haematoma
116277856 11627785 Haemoptysis
116277856 11627785 Haemorrhage
116277856 11627785 Head injury
116277856 11627785 Headache
116277856 11627785 Impaired healing
116277856 11627785 Incorrect drug administration rate
116277856 11627785 Incorrect route of drug administration
116277856 11627785 Increased tendency to bruise
116277856 11627785 Influenza
116277856 11627785 Injection site pruritus
116277856 11627785 Injection site reaction
116277856 11627785 Joint swelling
116277856 11627785 Laceration
116277856 11627785 Lacrimation increased
116277856 11627785 Laryngitis
116277856 11627785 Loss of consciousness
116277856 11627785 Lymphadenopathy
116277856 11627785 Malaise
116277856 11627785 Musculoskeletal pain
116277856 11627785 Myalgia
116277856 11627785 Nasopharyngitis
116277856 11627785 Odynophagia
116277856 11627785 Oropharyngeal pain
116277856 11627785 Pain in extremity
116277856 11627785 Peripheral vascular disorder
116277856 11627785 Rash
116277856 11627785 Renal pain
116277856 11627785 Rib fracture
116277856 11627785 Sinus congestion
116277856 11627785 Skin atrophy
116277856 11627785 Skin injury
116277856 11627785 Somnolence
116277856 11627785 Spider vein
116277856 11627785 Upper respiratory tract infection
116277856 11627785 Urticaria
116277856 11627785 Visual impairment
116277856 11627785 Wheezing

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
116277856 11627785 1 20130124 0
116277856 11627785 2 20130516 0
116277856 11627785 3 20130711 0
116277856 11627785 4 20131030 0
116277856 11627785 5 20131126 0
116277856 11627785 6 20140121 0
116277856 11627785 7 20140218 0
116277856 11627785 8 20150224 0
116277856 11627785 9 20150519 2015 0
116277856 11627785 10 20160627 0
116277856 11627785 11 20160728 0